Introduction
Injury to vascular endothelial cells is implicated in atherosclerosis and thrombosis
. Under normal conditions, endothelial nitric oxide synthase (eNOS) generates the vasoprotective molecule, nitric oxide [9, 10] . Vascular nitric oxide has a variety of functions, the most important being dilation of all types of blood vessels to maintain vascular homeostasis [10] . In atherosclerosis, a reduction in eNOS-derived nitric oxide impairs endotheliumdependent relaxation, with this impairment occurring before vascular structural changes arise [11] . Type 2 diabetes is associated not only with oxidant stress and accelerated endothelial apoptosis, but also with impaired endothelium-dependent relaxation [12, 13] .
Indeed, endothelial dysfunction characterized by reduced nitric oxide bioactivity is a critical component of accelerated atherosclerosis associated with type 2 diabetes. Both hyperglycaemia and dyslipoproteinemia have also been implicated in the acceleration of diabetic vascular complications.
Oxidized LDL promotes endothelial cell toxicity and vasoconstriction both in vitro and in vivo. Plasma levels of oxidized LDL correlate with endothelial dysfunction and are reduced following lipid-lowering therapy using apheresis or statins (reviewed by Navab et al. [14] ). Plasma levels of oxidized LDL were also recently shown to be an independent determinant of coronary macrovasomotor and microvasomotor responses elicited by bradykinin in human beings [15] . Circulating levels of oxidized LDL have been proposed to be a predictor of secondary cardiovascular events [16] . However, the molecular mechanisms by which HOG-LDL impairs endothelial dysfunction are poorly understood. Thus 
Materials and methods

Materials
MDL 28170 (carbobenzoxyl-valinyl-phenylalaninal) was purchased from Calbiochem (Gibbstown, NJ, USA). Other calpain inhibitors (ALLN, ALLM, calpeptin and E-64) and the fluorescent calpain substrate, Suc-leu-LeuVal-Tyr-AMC, were obtained from BioMol International (Plymouth Meeting, PA, USA). The Fluo-4 NW calcium assay kits, dihydroethidium (DHE) and 2Ј,7Ј-dichlorofluorescein (DCF) were obtained from Invitrogen (Carlsbad, CA, USA). Antibodies against eNOS, phospho-Ser1177 of eNOS and 3-nitrotyrosine-specifc antibody were obtained from Cell
Preparation of N-LDL and HOG-LDL
The isolation of LDL from human donors was approved by the Institutional Review Board at the University of Oklahoma Health Science Center. Both N-LDL and HOG-LDL were prepared as previously described [17] . 
Cell culture and treatment
Measurement of eNOS dimers/monomers
Levels of eNOS dimers/monomers were assayed using low-temperature SDS-PAGE, without boiling samples, as previously described [18] .
Immunocytochemical staining of eNOS and calpain 1
Calpain 1 and eNOS immunostaining was performed as described elsewhere [19] 
Measurement of calpain activity
Calpain activity assays were performed with a previously described method with minor modification [22] . 
Measurement of 26S proteasome activity
The 26S proteasome activity was assayed using the fluorogenic proteasome substrate, Suc-LLVY-7-amido-4-methylcoumarin, as detailed previously [23] . [23] .
Transfection of calpain 1-specific siRNA
Measurement of endothelium-dependent and -independent vasorelaxation
Western blot analysis
Total proteins were analysed by SDS-PAGE and blotted using standard protocols [24] . 
Results
HOG-LDL, but not N-LDL, suppresses the production of nitric oxide
Because nitric oxide is a key factor for maintaining vascular homeostasis, we tested the effect of HOG-LDL on nitric oxide production in BAECs. Confluent BAECs were exposed to HOG-LDL at a concentration of 100 g/ml, which is considered to be pathologically relevant to type 2 diabetes [25] . A 6-hr exposure to HOG-LDL decreased nitric oxide levels by 78%, whereas N-LDL had no effect (Fig. 1A) .
HOG-LDL, but not N-LDL, elicits a dose-and time-dependent reduction in eNOS
Next, we investigated whether HOG-LDL reduces nitric oxide production in BAECs by lowering total eNOS protein levels. No appreciable change in total eNOS protein levels was observed at 3 hrs of HOG-LDL (100 g/ml) incubation; however, total eNOS levels were progressively decreased by 60% at 6 hrs and 80% at 9 hrs after incubation (Fig. 1B) . The effects of HOG-LDL were also dose-dependent. As shown in Fig. 1C , a 6-hr incubation with 100 g/ml or 200 g/ml HOG- (Fig. 1D) . 
LDL reduced total eNOS levels by 60% and 80%, respectively. Because the zinc-thiolate cluster of eNOS is essential for eNOS activity and eNOS is active only as a dimer, we investigated whether HOG-LDL may selectively decrease levels of eNOS dimers. A 6-hr exposure to HOG-LDL (100 or 200 g/ml), but not N-LDL, reduced the levels of eNOS dimers and monomers to a similar degree
HOG-LDL does not alter eNOS transcription or directly degrade eNOS
To determine if reduction of eNOS protein levels by HOG-LDL was due to inhibition of eNOS transcription, we tested the effect of HOG-LDL treatment on eNOS mRNA levels in
versus untreated control or N-LDL (100 g/ml). (D) Western blot analysis of dimeric and monomeric eNOS in BAECs exposed to N-LDL or the indicated concentration of HOG-LDL. * ,# P < 0.01. HOG-LDL versus untreated controls or n-LDL. (E) Real time qPCR analysis of eNOS in BAECs treated with 100 g/ml N-LDL or HOG-LDL. PCR was performed with three pairs of independent eNOS primers, n ϭ 3 for each group. (F) Effect of increasing concentrations of HOG-LDL on recombinant eNOS protein levels (total, monomeric and dimeric). HOG-LDL was incubated with recombi
HOG-LDL-enhanced eNOS reduction is independent of 26S proteasomes
Because HOG-LDL did not alter eNOS levels in a cell-free system and eNOS reduction in BAECs required at least a 3-hr incubation with HOG-LDL, we speculated that HOG-LDL might reduce eNOS levels by inducing eNOS degradation. Studies [26, 27] suggest that eNOS is degraded by several mechanisms, including those involving 26S proteasomes and calcium-dependent calpain. As shown in Fig. 2A , exposure of BAECs to HOG-LDL (100 g/ml for 6 hrs) did not alter 26S proteasome activity. In addition, neither HOG-LDL nor N-LDL affected the levels of protein ubiquintination (Fig. 2B) . Furthermore, eNOS reduction by HOG-LDL was unaffected by co-administration of MG132, a potent proteasome inhibitor (Fig. 2C) . Taken together, these results suggest that HOG-LDL-induced reduction in eNOS occurs independently of 26S proteasomes.
HOG-LDL increases calpain activity and eNOS translocation to the cytoplasm, where calpains reside
Calpains are Ca 2ϩ -dependent cysteine proteases which are implicated in a large number of physiological processes [28, 29] . Calpain activity assays revealed that HOG-LDL markedly increased the calpain activity in BAECs (Fig. 2D) . Exposure of BAECs to HOG-LDL for 6 hrs led to cleavage of the calpain substrate, caspase-12 [30] , confirming that HOG-LDL induces calpain activation (Fig. 2E) .
If eNOS is degraded by calpain, then a physical association between these two proteins would be required. However, eNOS exists predominantly in caveolae of the plasma membrane [31] , whereas calpains exist mainly in cytoplasm. Thus, we investigated whether HOG-LDL alters the subcellular localization of eNOS in BAECs. After 2 hrs treatment, both immunocytochemical staining (Fig. 2F) and Western blot analysis of membrane and cytosolic fractions (Fig. 2G) (Fig. 3A-C (Fig. 3D) . Calpain 1-specific siRNA partially prevented eNOS reduction by HOG-LDL, whereas control siRNA had no effect (Fig. 3D ).
HOG-LDL increases cytosolic Ca 2ϩ levels
Calpain activity is strictly controlled by intracellular Ca 2ϩ , prompting us to test if calpain activation by HOG-LDL is Ca 2ϩ -dependent. HOG-LDL (Ͼ50 g/ml) induced a pronounced elevation in intracellular Ca
2ϩ in BAECs, whereas N-LDL (100 g/ml) had no effect (Fig. 4A) 
Inhibition of HOG-LDL-induced elevation in intracellular Ca 2ϩ prevents eNOS degradation
HOG-LDL increases the formation of ROS and the membrane translocation of the p47 phox NAD(P)H oxidase subunit
Recent studies by our laboratory and others suggest that ROS cause the vascular injury induced by oxidized LDL (See review [32]). Thus, we hypothesized that ROS mediate the elevation in intracellular Ca 2ϩ and subsequent calpain activation by HOG-LDL.
In accordance with this hypothesis, HOG-LDL increased O2
Ϫ levels by ~ 4-fold (P < 0.01), whereas N-LDL had no effect (Fig. 5A ).
In addition, H2O2 was increased approximately twofold following 6 hrs of HOG-LDL treatment (Fig. 5B). The formation of O2 Ϫ in HOG-LDL-exposed BAECs was significantly suppressed by inhibition of NAD(P)H oxidase with apocynin (data not shown), suggesting that NAD(P)H oxidase may contribute to HOG-LDL-induced oxidative stress. Western blot analysis of subcellular fractions revealed that HOG-LDL induced p47
phox translocation from the cytosol to the plasma membrane (Fig. 5C ), a signature of NAD(P)H oxidase activation [33] . The p47 phox membrane translocation was not seen in N-LDL-treated [34] .
BAECs. These results suggest that HOG-LDL activates NAD(P)H oxidase, consistent with a previous report
Inhibition of ROS formation attenuates HOG-LDL-induced elevation in intracellular Ca 2ϩ
Blocking Ca 2ϩ influx with EGTA in HOG-LDL-treated BAECs not only prevented eNOS degradation, but also dramatically reduced O2
Ϫ and H2O2 production ( Fig. 5D and E) . Accordingly, inhibition (Fig. 5G) (Fig. 6A) did not affect eNOS levels. In contrast, exposure of aortas to 100 g/ml HOG-LDL for 24 hrs reduced eNOS protein levels by 75-80% (P < 0.05, Fig. 6A ). Importantly, this reduction in aortic eNOS levels was almost completely blocked by co-administration of MDL28170 (Fig. 6A) . (Fig. 6B) . MDL28170 alone has no effect on vasorelaxation. However, Ach-induced vasodilatation (Fig. 6C) . Together, these data suggest that calpain participates in HOG-LDL-induced endothelial dysfunction.
of NAD(P)H oxidase activity with apocynin or DPI attenuated increases in intracellular Ca 2ϩ (Fig. 5F) as well as eNOS degradation © 2008 The Authors Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 2 HOG-LDL selectively activates calpain and induces cytoplasmic translocation of eNOS (A) Effect of HOG-LDL on 26S proteasome activity in BAECs. n ϭ 3; ns, non significant difference for control versus HOG-LDL. (B) Effect of HOG-LDL on protein ubiquitination in BAECs, as determined by Western blot analysis. n ϭ 3 for each group. (C) Western blot analysis of eNOS levels in BAECs exposed to HOG-LDL in the presence or absence of MG132. The blot is a representative of four blots obtained from four separate experiments. *P < 0.01 HOG-LDL versus control; NS, no significant difference. (D) Calpain activity in BAECs treated with N-LDL (100 g/ml) or increasing concentrations of HOG-LDL for 6 hrs n ϭ 3, **P < 0.01 versus untreated controls or n-LDL. (E) Effect of HOG-LDL on caspase 12 cleavage. The blot is representative of three separate experiments. (F) Confocal images (400ϫ) of eNOS immunofluorescent staining in control and HOG-LDL-treated BAECs. Note the redistribution of eNOS from the plasma membrane to the cytoplasm in the presence of HOG-LDL. (G) Western blot analysis for eNOS in membrane and cytosolic fractions isolated from control or HOG-LDL-treated BAECs. n ϭ 3 for both groups. in HOG-LDL-treated BAECs
HOG-LDL reduces aortic eNOS levels and impairs endothelial function in a calpain-dependent manner
Next, we determined whether HOG-LDL induces calpain-dependent eNOS degradation in intact aortas. Isolated mouse aortas were exposed to either N-LDL or HOG-LDL in the presence or absence of MDL28170, and eNOS protein levels were measured. Exposure of mouse aortas to MDL28170 alone (data not shown) or N-LDL
To investigate the role of HOG-LDL-induced calpain activation in endothelial dysfunction, we tested the effect of N-LDL, HOG-LDL and HOG-LDL ϩ MDL28170 on endothelium-dependent and -independent vasorelaxation under ex vivo conditions. Acetylcholine induced concentration-dependent arterial vasodilatation in all treatment groups
Discussion
Nitric oxide from eNOS plays essential role in maintaining vascular homeostasis [35] . Reduced nitric oxide generation and/or bioavailability have been implicated in the pathophysiology of several disease states including coronary artery disease, hypertension, diabetes and heart failure [36, 37] 
